Shilpa Medicare Q1 FY27: A record quarter, with the platform starting to monetize

Shilpa Medicare opened FY27 with its strongest quarterly performance so far. In Q1 FY27, consolidated revenue rose to INR 469 crore, up 43% year on year, while EBITDA increased to INR 139 crore, up 42% year on year. EBITDA margin held steady at 30%. Reported profit after tax came in at INR 101 crore, up 115% year on year.

Management used the quarter to frame a broader shift in what the company is becoming. In the earnings call, leadership pointed to a multi-year transformation from a more traditional API-led model to an integrated platform spanning APIs, complex formulations, biologics, CDMO, and emerging areas such as ADCs and recombinant human albumin. The company also highlighted a credit rating upgrade from A+ to AA-, which it linked to an improving balance sheet and return ratios.

The quarter in numbers

The income statement showed both growth and operating leverage. Gross profit was INR 334 crore with a gross margin of 71%. EBITDA was INR 139 crore, and operating PBT was INR 92 crore. The company noted a negative tax rate in the quarter due to reversal of deferred tax liability as it plans to shift to a new tax regime, with management expecting the tax rate to normalize to around 25% in coming quarters.

Segment performance: growth across all three verticals

Shilpa’s revenue mix in Q1 FY27 remained diversified across three operating verticals. APIs contributed 47% of revenue, formulations contributed 42%, and biologics contributed 11%.

API revenues were supported by steady captive demand from the finished dosage formulation business and improved traction in third-party business. The company’s presentation highlighted that non-captive portfolio growth was driven by specialty CDMO, supported by new customer acquisitions in developed markets.

Formulations delivered the fastest growth in the quarter. The company reported that formulations revenue grew over 100% year on year, with US revenue at INR 45 crore and Europe formulations revenue at INR 57 crore. Domestic formulations revenue was INR 24 crore, with management attributing growth to order visibility and commercial traction following the NorUDCA launch in India. Licensing and services income within the formulations segment was INR 29 crore in Q1 FY27.

Biologics reported Q1 FY27 revenue of INR 52 crore, up 42% year on year. Management linked this growth to continued deal momentum in licensing, partnerships, and CDMO.

Pipeline and capacity: from investment phase to utilization

A recurring theme in both the investor presentation and the concall was operating leverage, driven by improved utilization of assets built over the last few years. Management said a substantial portion of the current gross block remains underutilized, particularly across higher-margin divisions such as biosimilars, CDMO and NDDS, and that better utilization could support both revenue growth and margin improvement.

In APIs, the company is expanding its oncology portfolio and capacity. The presentation stated that the oncology API pipeline has been revamped with 15+ new APIs and targets products facing patent expiries through 2032. A new oncology block expansion is underway and is slated for completion by end of FY27. Management also discussed further expansion of capacity for key products such as UDCA and Tranexamic Acid.

The concall added another key capex focus within APIs: peptide manufacturing. Management said it is making a large capital investment in peptide capacity in India, with end-to-end solid-phase synthesis capability, and commissioning expected by end of FY27.

In formulations, the company continued to highlight its complex pipeline. The presentation noted that Rotigotine transdermal patch received final marketing authorization from the EMA, with an EU launch planned in 1H FY27 and US approval expected in FY27. Other complex assets included Ondansetron ER, where the company highlighted a planned FY27 launch in India and a global development pathway for regulated markets.

In biologics, Shilpa outlined multiple programs across biosimilars, novel biologics and integrated platforms. Aflibercept biosimilar is targeting an FY27 India launch, with Phase III nearing completion in 1H FY27. The company also highlighted its partnership with Orion Corporation for a nivolumab biosimilar for Europe, where Orion will handle commercialization and Shilpa will earn development and regulatory milestones along with supply revenue.

The presentation emphasized its ADC platform as a differentiator, noting a commissioned integrated ADC drug substance GMP facility in Dharwad and the expectation that its first ADC biosimilar will enter human studies in FY27.

What management said to watch

The company avoided providing explicit forward guidance on revenue or margins, but management commentary did offer a few clear directional markers.

First, the company expects tax rates to normalize at around 25% after the one-off impact in Q1 FY27.

Second, management repeatedly highlighted that the heavier capex cycle in biologics and certain niche segments is largely behind it, and the next phase is monetization through improved capacity utilization. This does not mean capex stops entirely, as the company still plans selective investments in areas with higher utilization such as peptides.

Third, management acknowledged that regulatory pathways remain a key swing factor. The CFO stated that unexpected regulatory challenges could slow down growth trajectories, even as the company works to maintain strong compliance.

On margins, management described the current EBITDA margin around 30% as sustainable in the near term. The CFO also cited raw material price increases due to global political situations as a factor affecting gross margins, while noting that only part of these costs can be passed through.

Takeaways for investors

Shilpa Medicare’s Q1 FY27 performance was not a one-off spike driven by a single segment. The quarter reflected growth across APIs, formulations, and biologics, with steady operating margins and improving return metrics highlighted in the presentation.

The bigger story is the platform the company has built. The presentation and the concall both reinforced that Shilpa is positioning as an integrated player in complex and novel therapies, spanning everything from oncology APIs and specialty CDMO to transdermal delivery systems, biosimilars, ADCs, and recombinant human albumin.

Execution will still be tied to regulatory outcomes and partner-driven timelines, especially in CDMO and select programs such as Unicycive’s OLC. But the combination of record quarterly numbers, an improving balance sheet, and a detailed pipeline roadmap suggests that the next leg of the story is increasingly about utilization and scale, rather than just investment.